Trials: Lymphoma

You are here:

Find a Clinical Trial
Lymphoma

NCT01166009 – National Marrow Donor Program Research Database for Hemotopoietic Stem Cell Transplantation and Marrow Toxic Injuries

July 24, 2024

NCT03933904 – A Phase II, Single-Arm Open-Label Multi-Center Study of Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease

July 8, 2024

NCT04400591 – Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release

July 24, 2024

NCT04637763 – A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

September 18, 2024

NCT04799275 – S1918 A Phase II/III Randomized Study of R-MiniCHOP with or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC AND BCL2 and/or BCL6 Rearrangements

June 20, 2024

NCT04920474 – Protocol for a Research Sample Repository for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation

June 20, 2024

NCT05544032 – An Open-Label, Expanded Access Program of Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease in Participants Who Have Received at Least 2 Lines of Systemic Therapy

December 6, 2024

NCT05578976 – A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)

June 20, 2024

NCT05633615 – S2114: A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma

June 20, 2024

NCT05972720 – An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants with Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T-cell Therapy

June 20, 2024